bioRxivBioinformaticsPreprint
Systematic assessment of the biological impact of cellular deconvolution on downstream analyses of disease transcriptomes
Abstract
Background Cellular deconvolution methods estimate cell type proportions from bulk RNA seq data, typically using single cell RNA seq derived signatures, enabling separation of disease associated transcriptional changes into composition driven and cell intrinsic effects. However, these approaches depend on model assumptions and the stability of cell type signatures, and it remains unclear how deconvolution related uncertainties influence downstream analyses and biological conclusions. Results We systematically evaluated the effect of cell type correction on disease relevant transcriptomic insights, using Alzheimer's disease (AD) as a model and the Mount Sinai Brain Bank cohort as a primary dataset. Applying dtangle, selected after comparison with another deconvolution approach, we estimated cell type proportions across four brain regions and assessed how correction reshaped differential gene expression and pathway enrichment. Cell type correction (CTC) markedly altered differentially expressed gene (DEG) profiles in a region dependent manner: the superior temporal gyrus lost all significant signals, while the frontal pole gained DEGs with improved cross region concordance. At the pathway level, correction shifted enrichment from synaptic loss and immune activation toward suppression of stress response and immune regulatory programs, suggesting that composition changes partly obscure cell intrinsic regulatory signals. Overlap with AD genome wide association study loci and replication in an independent cohort indicated that cell intrinsic changes are more consistently validated than composition driven changes. Notably, KCNN2 and RIMS1, not currently recognized as canonical AD biomarkers, emerged as robust transcriptional signatures, potentially reflecting both compositiondriven and cell intrinsic dysregulation and warranting further investigation. Conclusions Parallel evaluation of uncorrected and CTC analyses distinguishes composition driven from cell intrinsic transcriptional effects and highlights robust disease signatures in heterogeneous tissues such as the brain.
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- research focus: gene regulatory network inference
- research focus: benchmarking
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Deciphering cellular transcriptional alterations in Alzheimer's disease brains
Xue Wang, Mariet Allen, … Nilüfer Ertekin‐Taner·Molecular NeurodegenerationPeer-reviewed·Jul 13, 2020
- Comprehensive evaluation of human brain gene expression deconvolution methods
Gavin J. Sutton, Daniel Poppe, … Irina Voineagu·Nature CommunicationsPeer-reviewed·Mar 15, 2022
- Evaluating performance and applications of sample-wise cell deconvolution methods on human brain transcriptomic data
Rujia Dai, Tianyao Chu, … Chunyu Liu·Science AdvancesPeer-reviewed·May 23, 2024
- DALE-Eval: A comprehensive cell type-specific expression deconvolution benchmark for transcriptomics data
Mengying Hu, Martin Jinye Zhang, Maria D. Chikina·bioRxiv·Jul 31, 2025
- Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure
Zeran Li, Jorge L. Del‐Aguila, … Oscar Harari·Genome MedicinePeer-reviewed·Jun 6, 2018
- A single-cell atlas of the human brain in Alzheimer's disease and its implications for personalized drug repositioning
Guangsheng Pei, Brisa Simões Fernandes, … Zhongming Zhao·bioRxiv·Jun 14, 2022